Main Therapeutic Uses

Элоком (Mometasone furoate) is a synthetic corticosteroid used to manage various inflammatory and pruritic skin conditions. It is primarily indicated for the relief of symptoms associated with dermatoses that respond to topical steroid treatment.

Primary Conditions Treated

• Atopic Dermatitis: Helps reduce the redness, swelling, and itching associated with chronic eczema flares.
• Psoriasis: Used to manage plaque psoriasis, helping to thin thickened skin patches and reduce scaling.
• Allergic Contact Dermatitis: Addresses skin reactions caused by contact with allergens or irritants.
• Seborrheic Dermatitis: Can be used to manage inflammatory symptoms on the scalp or face.

Benefits and Mechanism of Action

As a medium-potency corticosteroid, the medication provides targeted relief by acting directly on the affected skin cells. Its primary benefits include:

Anti-inflammatory Action

It inhibits the release of inflammatory mediators and stabilizes cell membranes. This reduces the visible signs of skin irritation, such as redness (erythema) and swelling (edema).

Antipruritic Effect

One of the most significant benefits for patients is the rapid reduction of itching (pruritus). By suppressing the underlying inflammatory response, it helps break the itch-scratch cycle, which is essential for skin healing.

Vasoconstrictive Properties

The medication induces vasoconstriction, which helps limit the flow of inflammatory cells to the site of the skin lesion, further reducing the intensity of the localized reaction.

Who Can and Cannot Use Элоком?

The population eligibility for Mometasone Furoate is strictly defined by regulatory authorities.

Absolute Contraindications

The medicine is strictly contraindicated for any individual with a known hypersensitivity or allergy to Mometasone Furoate or any other inactive ingredient in the specific formulation. This officially prohibits use in the allergic population.

Age and Pediatric Restrictions

Eligibility is defined by age thresholds. Topical cream and ointment are approved for patients 2 years of age and older. Use is not recommended for children below this age or for those younger than 12 years of age when using the topical lotion formulation. Pediatric patients are identified as being more susceptible to potential systemic effects.

Conditional Use and Prohibitions

Use is prohibited for infants in the diaper area, as the material acts as an occlusive dressing, increasing the risk of systemic absorption. Nasal use is also prohibited until healing has occurred following recent nasal surgery, trauma, or ulcers. Use requires caution in patients with specific underlying conditions, such as hepatic impairment or untreated systemic infections.

Reproductive Status

During pregnancy, use is conditional and permitted only if the potential benefit justifies the potential risk to the fetus. For lactation, a decision to discontinue breastfeeding or discontinue the drug is required due to the unknown risk of excretion into human milk.

Interactions with other medicines and products

The official interaction profile for Mometasone Furoate (the active ingredient in Элоком) is primarily structured around a pharmacokinetic interaction related to its metabolism. This profile is consistent across regulatory documents from agencies like the EMA and FDA.

---

Pharmacokinetic Interaction Risk

Co-administered drugs that strongly inhibit the Cytochrome P450 3A (CYP3A) enzyme system have been shown to inhibit Mometasone Furoate metabolism, resulting in increased systemic exposure of the corticosteroid. This increase carries a heightened risk of systemic corticosteroid side-effects, such as HPA axis suppression.

• Interacting Agents: Specific strong CYP3A inhibitors cited in official documents include Cobicistat, Ritonavir, and Itraconazole.

---

Regulatory Restrictions and Conditions

Co-treatment with strong CYP3A inhibitors is officially restricted and should be avoided unless the potential benefit is judged to outweigh the increased risk. If co-administration is necessary, regulatory information requires patients to be closely monitored for evidence of systemic corticosteroid effects.

• Population Note: Patients with conditions that affect drug clearance, such as liver failure, are noted as having increased susceptibility to the systemic effects of Mometasone Furoate, making the risk associated with this interaction more pronounced.

No specific pharmacodynamic, transporter-mediated, or food/alcohol interactions are explicitly documented in the core regulatory labels. For the topical cream formulation, official documentation notes that no drug-drug interaction studies have been formally conducted.

Mometasone Furoate initiates a multi-layered mechanism that begins at the cellular nucleus, engaging biological targets to modulate physiological processes.

---

Genomic Control of the Inflammatory Response

The initial mechanism involves the drug binding to the cytoplasmic Glucocorticoid Receptor (GR). This activated complex enters the cell nucleus to modulate gene expression, primarily by directly suppressing (transrepression) pro-inflammatory transcription factors like Nuclear Factor-kappaB (NF-kappaB). This action restricts the cell's ability to produce inflammatory and immune-recruiting molecules (cytokines and chemokines), thereby modulating the cascade.

---

Pathway Blockade and Eicosanoid Inhibition

The genomic action simultaneously induces the synthesis of the protein Lipocortin-1 (Annexin A1), a protein that acts as an inhibitory signal. Lipocortin-1 acts to inhibit the enzyme Phospholipase A2 (PLA2), which is essential for releasing Arachidonic Acid—the precursor to major inflammatory mediators. This upstream blockade reduces the generation of pro-inflammatory compounds, such as prostaglandins and leukotrienes.

---

Local Vascular and Cellular Modulation

The molecular suppression of inflammatory mediators translates into two key physiological consequences at the tissue level: localized vasoconstriction (narrowing of small blood vessels) and reduced capillary permeability. This reduces the amount of fluid extravasation and immune cell infiltration into the tissue, resulting in localized vascular constriction and a reduction in tissue edema.

Administration Scope

Category	Instruction
Route of administration	Topical (for Cream, Ointment 0.1%) and Intranasal (for Aqueous Suspension Nasal Spray).
Dosing schedule	Topical: Apply a thin film to the affected skin area once daily. Intranasal: Standard adult dose is 200 mu g once daily (two sprays in each nostril). The maximum daily dose for nasal polyps is 400 mu g (twice daily).
Timing in relation to meals (if applicable)	Not dependent on meal timing.
Preparation requirements (if applicable)	The nasal spray must be shaken well before each use. The pump requires priming (e.g., ten actuations) before initial use and must be re-primed if unused for over one week.
Age-group administration rules	Pediatric Topical: Treatment should be limited in duration, with courses on the face typically restricted to no more than 5 days. Pediatric Intranasal (3–11 years): 100 mu g once daily (one spray in each nostril).
Missed-dose rules	If a dose is missed, administer it as soon as possible, or skip it if it is near the next scheduled dose. Double doses are prohibited.
Special procedural conditions	Topical: Avoid use with occlusive dressings. Intranasal: Prophylaxis may begin 2 to 4 weeks prior to the anticipated start of the pollen season.

---

Instruction Classifications (high-level)

Classification	Detail
Administration method type	Topical (dermatological) and Intranasal (localized nasal delivery).
Frequency pattern	Once Daily (QD) is the primary frequency, with an approved escalation to Twice Daily for certain intranasal indications.
Standardization basis	Governed by standardized clinical documentation and pharmaceutical specifications.
Use-context constraints	Time-bound use; area-bound use (e.g., no more than 10% BSA in children); titration/step-down dosing.

---

Resulting procedural structure

Official step sequence:

• Identify the correct formulation based on the site of application (topical or intranasal).
• For the nasal spray, shake the container well and prime the pump according to the initial-use or re-priming schedule.
• Administer the dosage exactly as indicated by the established protocol: once daily for topical application (thin film) or the specified microgram dose for intranasal use.
• Adhere strictly to duration limits, discontinuing topical use after the specified short course duration or for use on the face.

Connection to the overall use protocol: The instructions establish a precise protocol that dictates the route, exact dose, and duration of the medication based on the formulation type. This structure mandates specific administration steps, such as spray priming and application quantity limits, to ensure standardized delivery. Furthermore, the protocol incorporates adjustments for pediatric patients and defines clear time constraints for treatment, reflecting established requirements for use.

Research evidence / Overview of studies for Элоком

Evidence for Use in Inflammatory Skin Conditions

The research base primarily consists of short-term Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms linked to inflammatory or irritative states, such as Atopic Dermatitis (Eczema) and Psoriasis. Researchers examined outcomes related to physical discomfort by measuring standardized scoring systems for disease severity, along with objective signs like redness (erythema) and swelling (induration). These trials often included a comparison group receiving a placebo, which was a cream or ointment base without the active ingredient.

Studies conducted during periods of increased symptom activity described patterns related to how symptoms evolved in the observed populations over short treatment phases, typically lasting only a few weeks. Controlled data on the long-term continuous use of the topical formulations is not well characterized by large-scale studies. Research exploring long-term use patterns remains varied and subject to study design differences.

Evidence for Use in Allergic and Inflammatory Nasal Conditions

The intranasal formulation of Mometasone Furoate (nasal spray) was studied for conditions characterized by fluctuating or episodic manifestations, including Seasonal and Perennial Allergic Rhinitis. The research has explored outcomes reflecting daily functioning, specifically monitoring changes in the Total Nasal Symptom Score (TNSS), which combines patient-reported outcomes describing perceived discomfort such as nasal congestion, sneezing, and runny nose. This evidence is derived from multiple large-scale RCTs.

Evidence for Allergic Rhinitis Studies

Studies focusing on episodes where symptoms become more noticeable reported changes measured during the short-term study period, typically up to four weeks. Findings indicate that the measured change in symptoms often requires a period of consistent use (e.g., up to 48 hours) before changes in symptom measurements are fully described.

Evidence for Nasal Polyposis Studies

The intranasal formulation was evaluated in studies for patients with Nasal Polyposis. These medium-term studies, generally lasting about four months, used a different set of primary outcomes. Research monitored objective physiological strain by assessing changes in the size or grade of the polyps, as determined by a physician.

Evidence Gaps and Areas of Uncertainty

The evidence landscape contributes to understanding symptom patterns, but not all questions are definitively addressed. There is limited information for long-term outcomes, especially regarding the recurrence of conditions or the need for sustained use over many years. Furthermore, comprehensive, direct, head-to-head comparisons against all alternative treatments are not widely available, and the relative certainty of findings varies across studies. Findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.

Key Studies & References

1. Label: MOMETASONE FUROATE spray, metered - DailyMed - NIH (Regulatory/Indication source)

Common questions about Citalopram (FAQ)

---

Q: How should I store Citalopram tablets?

Official drug information advises storing Citalopram tablets at room temperature, which is typically defined as 68 F to 77 F (20 C to 25 C). The medicine is generally recommended to be kept in its original container, tightly closed, and stored out of the sight and reach of children.

---

Q: Does Citalopram make you sleepy?

Changes in sleep patterns, such as sleepiness (somnolence) or trouble sleeping (insomnia), are listed as common adverse effects in the official product labeling for Citalopram. This information is found in the Undesirable Effects or Adverse Reactions section of regulatory documents.

---

Q: Is Citalopram safe long-term?

Regulatory documents mention the use of Citalopram for maintenance treatment in adults intended to help delay the return of depressive episodes. However, regulatory warnings note that when Citalopram is used for long-term treatment, ongoing monitoring is advised. This monitoring covers potential issues like Hyponatremia (low sodium levels) and the emergence of suicidal thoughts or behaviors.

---

Q: Can children 2 years old use Citalopram?

Official product labeling indicates that Citalopram is not approved for use in pediatric patients, meaning children and adolescents under 18 years of age. Regulatory guidance generally advises against its use in this population due to limited data on long-term safety and effectiveness.

---

Q: Does Citalopram affect my ability to drive or operate machinery?

Official prescribing information advises caution, as Citalopram can potentially cause side effects such as dizziness, fatigue, or visual disturbance. Due to these possible effects, it is recommended that individuals wait and observe how the medicine affects them before engaging in activities like driving or operating hazardous machinery.

How to Store and Dispose of Elokom (Mometasone Furoate)

Elokom storage and disposal requirements are strictly defined by regulatory labeling to maintain product stability and ensure safety.

Storage Requirements

The product must be stored at Controlled Room Temperature, typically between 15 C and 30 C (59 F and 86 F). It is mandatory to keep the medication away from heat, moisture, and direct light, and it must not be frozen.

Stability and Handling

For child safety, the medication must be stored out of the sight and reach of children.

The official labeling defines specific post-opening stability periods; for instance, the nasal spray should be discarded after a set number of sprays or a defined time period after first use. Patients using topical forms are warned that residue on fabrics (like bedding or clothing) presents a fire hazard, and they must avoid naked flames.

Disposal Mandates

Do not dispose of unused or expired Elokom via household waste or wastewater. Patients are instructed to consult a pharmacist to ensure the medication is disposed of safely and in accordance with local environmental regulations.